Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
Xconomy
JANUARY 4, 2019
You’ll find a few of our favorite stories in this review of some of the year’s best from across the Xconomy network. Topics ranged from the worries over CRISPR genome editing and Wild West biohacking, to Nobel Prize-fueled drug approvals and the headaches around drug prices (even for drugs meant to cure headaches).
Let's personalize your content